Oncoclínicas (ONCO3) reported this Wednesday, July 15, 2026, that it received from IG4 Capital Investimentos an indicative non-binding offer for a potential transaction involving the subscription of convertible debentures (debt securities that can be converted into shares) in the total amount of R$ 500 million. The proposal also provides for the establishment of usufruct over shares issued by the company, subject to an agreement with the shareholder base, among other prior and cumulative conditions.
The company clarified that receipt of the non-binding offer does not imply acceptance, commitment, or obligation on the part of Oncoclínicas. According to the statement, there is no definition regarding a possible transaction with IG4 Capital or any other interested party, and the company says it will keep the market informed should any material facts arise on the matter.
In the same statement, Oncoclínicas responded to a question from the CVM regarding a news article published on July 14, 2026. The company stated that, on the date the article was released, it had not received any formal communication or proposal from IG4, and that up to that moment it did not have concrete, precise, and non-public information that would require disclosure under the applicable regulations.
